Cellink

Cellink is a biotechnology startup that designs bio-inks and bioprinters for culturing different cell types to enable applications like patient-derived implants.[2] Cellink was the first company to provide a standardized bio-ink product for sale over the internet.[1] The company has ongoing collaborations with organizations including MedImmune, MIT and Takara Bio, and its printers are used for research at Harvard University, Merck, Novartis, the U.S. Army, Toyota, Johnson & Johnson and more.

Cellink
Public
Traded as
Industry
FoundedJanuary 27, 2016 (2016-01-27) in Gothenburg, Sweden
Founders
Headquarters
Boston
,
United States
Area served
Worldwide
Key people
RevenueUS$4.88 million (2018)
Number of employees
  • >200 (2020)
Websitewww.cellink.com
Footnotes / references
Revenue 2016, employees 2017[1]

A stated goal of the company is to help address the existing global shortage of organs suitable for human transplantation.[1]

History

Cellink was founded in 2016 by Erik Gatenholm, the company's chief executive, and Héctor Martinez.[1] They developed and sold the world's first universally compatible bio-ink to simplify bioprinting for academics and pharmaceutical companies who were, at that time, mixing their own biomaterial in-house.[1][3] The company released its first bioprinter to test the market in 2015, and continued designing additional bio-inks to support more specialized applications in bioprinting.[3]

Ten months after it was founded, Cellink was listed publicly on the Nasdaq exchange First North.[1] At its IPO, shares were oversubscribed by 1070 percent.[3]

In 2017, the company was described as "a world leader in bioprinting". It established a United States headquarters in Boston the same year.[1]

The company's revenue totaled $4.88 million in 2018.[4] As of February 2019, its products are used by more than 600 labs in more than 50 countries.[5]

Cellink acquired German biotechnology company Cytena in August 2019 for a purchase price of $33.8 million.[6][7]

Products

The bio-ink produced by the company contains cellulose and alginate, locally sourced from trees in Sweden and seaweed from the Norwegian Sea, respectively.[1] Cellink's bio-ink technology was developed at Chalmers University.[1]

As of 2017, the company's bio-inks were priced in the range of US$9 and $299, while its bioprinters were priced in the US$10,000 to $40,000 range.[1]

An integral part of the company's customer service is to train customers at their sites and ensure that they can successfully use the technology.[1]

See also

References
  1. Savage, Maddy (November 15, 2017). "The firm that can 3D print human body parts". BBC.
  2. Heater, Brian (March 24, 2017). "Swedish scientists successfully implant 3D-print human cartilage cells in baby mice". TechCrunch. Retrieved 25 Jan 2020.
  3. Dormehl, Luke (April 20, 2018). "Inside Cellink, the Swedish company building 3D printers for living tissue". Digital Trends. Designtechnica. Retrieved 25 Jan 2020.
  4. "A 3D Bioprinting Stock That's Not Organovo". Nanalyze. April 1, 2019.
  5. Beary, Brian (February 11, 2019). "ARAB HEALTH. CELLINK, A Market Leader in Bio-Ink Production". MedicalExpo e-magazine. Marseille, France. Retrieved 25 Jan 2020.
  6. Staff (August 5, 2019). "Cellink to Acquire Single-Cell Dispensing Firm Cytena for €30.3M". genomeweb. Crain Communications. Retrieved 25 Jan 2020.
  7. Listek, Vanesa (August 6, 2019). "CELLINK to acquire single-cell dispensing firm cytena for 30.3 million euros". 3DPrint.com. 3DR Holdings, LLC. Retrieved 25 Jan 2020.
This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.